Onconetix (NASDAQ:ONCO – Get Free Report) released its quarterly earnings data on Monday. The company reported ($76.01) earnings per share for the quarter, beating the consensus estimate of ($45,050.00) by $44,973.99, FiscalAI reports. The firm had revenue of $0.10 million during the quarter, compared to analysts’ expectations of $0.02 million. Onconetix had a negative net margin of 1,575.89% and a negative return on equity of 91.95%.
Onconetix Stock Up 1.7%
ONCO stock opened at $2.96 on Tuesday. Onconetix has a 52 week low of $2.76 and a 52 week high of $1,610.00. The company has a fifty day simple moving average of $6.09 and a two-hundred day simple moving average of $106.54. The firm has a market capitalization of $1.74 million, a P/E ratio of 0.00 and a beta of 2.62.
Wall Street Analyst Weigh In
A number of brokerages have recently issued reports on ONCO. Weiss Ratings raised shares of Onconetix from a “sell (e)” rating to a “sell (e+)” rating in a research report on Thursday, October 29th. Wall Street Zen raised Onconetix from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. One equities research analyst has rated the stock with a Sell rating. According to MarketBeat, the company has an average rating of “Sell”.
View Our Latest Analysis on ONCO
Onconetix Company Profile
Onconetix, Inc. is a biotechnology company focused on cancer-related diagnostics and therapeutics, with an emphasis on prostate health. Its portfolio includes Proclarix, a blood-based diagnostic test developed to help assess prostate cancer risk. Proclarix was developed by Swiss company Proteomedix, which Onconetix acquired in 2023. The test has received a CE mark for use in Europe; its availability and regulatory status may differ in other markets. Onconetix was formerly known as Blue Water Biotech before adopting its current name in 2024.
Recommended Stories
- Five stocks we like better than Onconetix
- 3 Stocks in an Overlooked Corner of Infrastructure With Hundreds of Billions at Stake
- Tyson Foods’ 10% Surge Puts a Breakout in Sight, But Wall Street Remains Cautious
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
Receive News & Ratings for Onconetix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconetix and related companies with MarketBeat.com's FREE daily email newsletter.
